Genomics Core Facility The goal of the Genomics Core Facility (GCF) is to make genomic analysis products and services widely available to UNC LCCC members at cost-effective prices. Services include: producing low-cost custom microarrays for model organisms;analysis of RNA quality;support of the use of Agilent and Affymetrix gene expression microarrays and aCGH and microRNA microarrays;RNAi screening services;assisting with experimental design and analyzing results;archiving of both Agilent and Affimetrix array data;providing web based pathway analysis software;and providing """"""""walk-up"""""""" quantitative PCR analysis. The Core adds value to the Center by making accessible complex and expensive DNA technologies to UNC LCCC members. Well-integrated genomics and bioinformatics groups interact with the microarray user to ensure robust data that is archived appropriately for future use. Highlights of research supported by the Core include: Jen Jen Yeh's profiling studies of gene expression in pancreatic cancers, Charles Perou's profiling of cancer gene expression and the effects of cancer therapeutics, and characterization of gene expression in a wide range of tumor types in support of the Cancer Genome Atlas (TCGA) Project. This year and next will see major changes. The Bioinformatics group, while remaining fully integrated, functionally is evolving into a separate core with multiple functions. The Genomics Core is also expanding to offer new techniques, including mapping of methylation sites, preparation of cDNA libraries from mRNA for mRNA-seq by the NexGen sequencing core;continuing development of an RNAi High-throughput Screening facility for functional genomics studies;and offering Nanostring technology for multiplex quantitative measurement of mRNA without amplification. Lastly, the Agilent and Affimetrix microarray components will be physically consolidated in newly renovated space with the DNA Sequencing, Mammalian Genotyping, and High Throughput (Next-Generation) Sequencing Facility. This will enable the cores to more fully integrate and flexibly service users. In 2009, the core was used by 91 investigators. Peer-review funded members accounted for 87% of total core use. Fifty-five Cancer Center members from eight programs used the core. CCSG funding of $167,411 is requested for 2010, representing 10% of the projected operating costs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594164
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$212,220
Indirect Cost
$66,183
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468
Zhang, Jing; Wu, Tao; Simon, Jeremy et al. (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361:290-295

Showing the most recent 10 out of 1525 publications